Mainly eliminated in unchanged form, in minor parts metabolised by CYP2C9. One reference and clinical observations point to non-porphyrinogenicity.

Angiotensin II receptor antagonist. Mainly eliminated in unchanged form, to a lesser extent metabolized in the liver by 2C9. Less potent inhibitor of CYP2C9.

Thunell, patient reports (n=5): tolerated. Andersson, patient report (n=1): tolerated.

Uneventful use reported in 44 patients with acute porphyria.